Identifying a predictive model for response to atypical antipsychotic monotherapy treatment in south Indian schizophrenia patients

Genomics

Volumn 102, Issue 2, 2013, Pages 131-135

  Gupta, Meenal ^a   Moily, Nagaraj S ^b   Kaur, Harpreet ^a   Jajodia, Ajay ^a   Jain, Sanjeev ^b   Kukreti, Ritushree ^a  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^b NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Antipsychotic drugs; Gene gene interaction; Logistic regression; Pharmacogenetics; Single nucleotide polymorphisms

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE 1 RECEPTOR; DOPAMINE 3 RECEPTOR;

ACCURACY; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRD1 GENE; DRD3 GENE; DRUG RESPONSE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC MARKER; HTR1A GENE; HTR3B GENE; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; ONSET AGE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RELIABILITY; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TREND STUDY;

AAP; ANTIPSYCHOTIC DRUGS; AREA UNDER THE CURVE; ATYPICAL ANTIPSYCHOTIC; AUC; CGI; CLINICAL GLOBAL IMPRESSIONS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS FOURTH REVISION; DSM IV; GENE-GENE INTERACTION; LOGISTIC REGRESSION; NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES; NEGATIVE PREDICTIVE VALUE; NIMHANS; NPV; PHARMACOGENETICS; POSITIVE PREDICTIVE VALUE; PPV; QC; QUALITY CONTROL; RECEIVER OPERATING CHARACTERISTIC; ROC; SCAN; SCHEDULES FOR CLINICAL ASSESSMENT IN NEUROPSYCHIATRY; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISMS; SNP; SPSS; STATISTICAL PACKAGE FOR SOCIAL SCIENCES; SZ; TAP; TYPICAL ANTIPSYCHOTICS;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; INDIA; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA;

EID: 84880945451     PISSN: 08887543     EISSN: 10898646     Source Type: Journal    
DOI: 10.1016/j.ygeno.2013.02.002     Document Type: Article

References (27)

1. Auquier P., Lancon C., Rouillon F., Lader M. Mortality in schizophrenia. Pharmacoepidemiol. Drug Saf. 2007, 16:1308-1312.
2. Nnadi C.U., Malhotra A.K. Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics. Curr. Psychiatry Rep. 2007, 9:313-318.
3. Arranz M.J., de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol. Psychiatry 2007, 12:707-747.
4. Gupta S., Jain S., Brahmachari S.K., Kukreti R. Pharmacogenomics: a path to predictive medicine for schizophrenia. Pharmacogenomics 2006, 7:31-47.
5. Kapur S., Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol. Psychiatry 2001, 50:873-883.
6. Potkin S.G., Basile V.S., Jin Y., Masellis M., Badri F., Keator D., Wu J.C., Alva G., Carreon D.T., Bunney W.E., Fallon J.H., Kennedy J.L. D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol. Psychiatry 2003, 8:109-113.
7. Lencz T., Robinson D.G., Xu K., Ekholm J., Sevy S., Gunduz-Bruce H., Woerner M.G., Kane J.M., Goldman D., Malhotra A.K. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am. J. Psychiatry 2006, 163:529-531.
8. Lane H.Y., Hsu S.K., Liu Y.C., Chang Y.C., Huang C.H., Chang W.H. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. J. Clin. Psychopharmacol. 2005, 25:6-11.
9. Ikeda M., Yamanouchi Y., Kinoshita Y., Kitajima T., Yoshimura R., Hashimoto S., O'Donovan M.C., Nakamura J., Ozaki N., Iwata N. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics 2008, 9:1437-1443.
10. Reynolds G.P., Arranz B., Templeman L.A., Fertuzinhos S., San L. Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am. J. Psychiatry 2006, 163:1826-1829.
11. Arranz M.J., Munro J., Owen M.J., Spurlock G., Sham P.C., Zhao J., Kirov G., Collier D.A., Kerwin R.W. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol. Psychiatry 1998, 3:61-66.
12. Yamanouchi Y., Iwata N., Suzuki T., Kitajima T., Ikeda M., Ozaki N. Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Pharmacogenomics J. 2003, 3:356-361.
13. Gutiérrez B., Arranz M.J., Huezo-Diaz P., Dempster D., Matthiasson P., Travis M., Munro J., Osborne S., Kerwin R.W. Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response. Schizophr. Res. 2002, 58:93-97.
14. Schuhmacher A., Mössner R., Quednow B.B., Kühn K.U., Wagner M., Cvetanovska G., Rujescu D., Zill P., Möller H.J., Rietschel M., Franke P., Wölwer W., Gaebel W., Maier W. Influence of 5-HT3 receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia. Pharmacogenet. Genomics 2009, 19:843-851.
15. Souza R.P., de Luca V., Meltzer H.Y., Lieberman J.A., Kennedy J.L. Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia. Pharmacogenet. Genomics 2010, 20:274-276.
16. Lane H.Y., Lin C.C., Huang C.H., Chang Y.C., Hsu S.K., Chang W.H. Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders. Schizophr. Res. 2004, 67:63-70.
17. Gupta M., Kaur H., Jajodia A., Jain S., Satyamoorthy K., Mukerji M., Thirthalli J., Indian Genome Variation Consortium, Kukreti R. Diverse facets of COMT: from a plausible predictive marker to a potential drug target for schizophrenia. Curr. Mol. Med. 2011, 11:732-743.
18. 3B for drug therapy in schizophrenia patients. Am. J. Med. Genet. B 2012, 159B:1006-1008.
19. Arranz M.J., Munro J., Birkett J., Bolonna A., Mancama D., Sodhi M., Lesch K.P., Meyer J.F., Sham P., Collier D.A., Murray R.M., Kerwin R.W. Pharmacogenetic prediction of clozapine response. Lancet 2000, 355:1615-1616.
20. Volpi S., Potkin S.G., Malhotra A.K., Licamele L., Lavedan C. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J. Clin. Psychiatry 2009, 70:801-809.
21. Wing J.K., Babor T., Brugha T., Burke J., Cooper J.E., Giel R., Jablenski A., Regier D., Sartorius N. SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Arch. Gen. Psychiatry 1990, 47:589-593.
22. McGuffin P., Farmer A., Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch. Gen. Psychiatry 1991, 48:764-770.
23. Guy W. Clinical global impressions. ECDEU Assessment Manual for Psychopharmacology, revised (DHEW Publ No ADM 76-338) 1976, 218-222. National Institute of Mental Health, Rockville, MD.
24. Gupta M., Chauhan C., Bhatnagar P., Gupta S., Grover S., Singh P.K., Purushottam M., Mukherjee O., Jain S., Brahmachari S.K., Kukreti R. Genetic susceptibility to schizophrenia: role of dopaminergic pathway gene polymorphisms. Pharmacogenomics 2009, 10:277-291.
25. Gupta M., Bhatnagar P., Grover S., Kaur H., Baghel R., Bhasin Y., Chauhan C., Verma B., Manduva V., Mukherjee O., Purushottam M., Sharma A., Jain S., Brahmachari S.K., Kukreti R. Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics 2009, 10:385-397.
26. Scheet P., Stephens M. A fast and flexible statistical model for large-scale population genotype data: applications to inferring missing genotypes and haplotypic phase. Am. J. Hum. Genet. 2006, 78:629-644.
27. Weinstein M.C., Fineberg H.V. Clinical Decisions Analysis 1980, Saunders, Philadelphia.